Lisata Therapeutics, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023, with comparison to fiscal 2022. Although the request metadata references 2022 Q4, this filing reports full-year 2023 results, not a standalone 2022 quarter.
Business context
Lisata is a clinical-stage pharmaceutical company developing therapies for solid tumors. Its lead candidate, LSTA1, is intended to improve delivery of co-administered anticancer drugs into tumors. LSTA1 was being studied in Phase 2a and Phase 2b trials across several solid-tumor types. The company has no approved products and has not generated product-sales revenue. Further development of its legacy CD34+ cell-therapy programs depends on finding a sufficiently funded strategic partner.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $12.7 million | $13.1 million |
| General and administrative expense | $13.0 million | $14.1 million |
| In-process research and development expense | $0 | $30.4 million |
| Total operating expenses | $25.7 million | $57.6 million |
| Operating loss | $(25.7) million | $(57.6) million |
| Net loss | $(20.8) million | $(54.2) million |
| Basic and diluted loss per share | $(2.58) | $(10.47) |
| Net cash used in operating activities | $(20.0) million | $(21.2) million |
At year-end 2023, cash and cash equivalents were $22.6 million and marketable securities were $27.9 million, totaling approximately $50.5 million. Working capital was $47.3 million; total assets were $54.7 million, total liabilities $6.8 million, and total equity $47.9 million. The balance sheet reports no debt balance. Cash and cash equivalents fell by $9.6 million during 2023. Investment income was $2.7 million, and the company recorded a $2.3 million income-tax benefit related primarily to the sale of New Jersey net operating losses.
Management said existing cash and marketable securities were expected to fund operating expenses for at least 12 months after the financial statements were issued. The company nevertheless expects to need substantial additional capital for continued development. Potential sources include equity or debt financing, partnerships, collaborations, grants, or asset sales; availability and terms are uncertain.
Material changes and notable items
- Net loss improved by $33.4 million year over year, mainly because 2022 included $30.4 million of acquired in-process R&D expense associated with the Cend acquisition. Excluding that item, operating expenses declined approximately $1.5 million, or 5.5%.
- Research and development spending decreased modestly as spending shifted toward LSTA1 trials, including the Phase 2a Bolster study, enrollment in the Phase 2b ASCEND study, manufacturing and CMC work, and glioblastoma study start-up.
- Operating cash use remained substantial at $20.0 million. Net cash provided by investing activities largely reflected net sales of marketable securities, rather than operating cash generation.
- The 2022 Cend merger was accounted for as an asset acquisition. Lisata issued approximately 3.77 million shares to Cend holders; the transaction and related reverse stock split materially affect comparisons of share counts and per-share data.
- In 2023, Lisata transferred its tumor-penetrating nanocomplex platform rights to Impilo for preferred shares. Certain related licenses were assigned to Impilo; the MIT license was terminated effective December 30, 2023.
Outlook, risks, and contingencies
- Clinical and regulatory risk: LSTA1 remains investigational; clinical results to date do not establish efficacy or assure regulatory approval. Trials may be delayed, fail to meet endpoints, or require additional studies.
- Early clinical evidence: The filing reports a 59% objective response rate among 29 evaluable patients in a completed Phase 1b first-line metastatic pancreatic cancer study. The comparison cited against the MPACT study is historical, not a randomized head-to-head comparison.
- Financing and dilution: Lisata expects continued losses and negative operating cash flow. It may need additional capital, which could be unavailable or dilutive; as of year-end, options, warrants, and restricted stock units represented potential issuance of approximately 2.9 million shares.
- Execution and supply: The company relies on third-party research and manufacturing organizations and had not qualified an alternate manufacturing supply. It also has no commercial sales and marketing organization.
- Litigation: Lingmed Limited alleges breach of contract and fraud relating to Cend’s Qilu collaboration agreement. Lisata denies the allegations and intends to defend the case; trial was scheduled for August 2, 2024. The filing does not provide a clear estimate of potential loss.
- Other exposure: Risks include dependence on LSTA1, intellectual-property and licensing matters, patient enrollment, reimbursement uncertainty, Australian R&D tax-credit eligibility, cybersecurity, and Nasdaq listing requirements.
- Controls and audit: Management concluded disclosure controls and internal control over financial reporting were effective as of year-end. The auditor issued an unqualified opinion on the financial statements, reported no critical audit matters, and was not engaged to audit internal controls.
Important facts for investors to verify
- Current cash, marketable securities, and actual operating cash burn relative to the stated minimum 12-month runway.
- Updated timelines, enrollment, safety findings, and results for ASCEND, Bolster, and other LSTA1 trials, including whether results are controlled and statistically persuasive.
- Financing plans and potential dilution, including use of the ATM facility and outstanding options, warrants, and equity awards.
- Status and possible financial exposure of the Lingmed litigation, and the terms and continuing value of licensing and collaboration arrangements.
- Eligibility and collection of Australian R&D tax incentives, and whether future partnership or licensing proceeds are realized.